INTRODUCTION
============

Excessive sugar consumption contributes to risk of cardiometabolic diseases.[@ref1] Despite global efforts to reduce consumption of sugar, it continues to exceed levels recommended by nutritional guidelines and is an important risk factor for cardiometabolic disease worldwide.[@ref1]-[@ref3] Sugar-sweetened beverages (SSBs) are a significant source of added sugars and have been identified as a critical contributor to high sugar intake.[@ref4] In the United States (US), consumption of SSBs is steadily increasing, especially among children and adolescents.[@ref5] Many Asian countries are following this global nutrition transition toward greater consumption of sugar and SSBs.[@ref6]-[@ref8]

Overconsumption of SSBs is linked to adverse health outcomes ranging from simple dental problems[@ref9] to overweight or obesity.[@ref10] Such changes ultimately lead to increases in metabolic abnormalities including fatty liver, dyslipidemia, type 2 diabetes mellitus (T2DM), and obesity.[@ref11] A recent meta-analysis of seven prospective cohort studies (n=308,420 participants; age range, 34--75 years) reported 13% greater risk of stroke and 22% greater risk of myocardial infarction associated with SSB consumption.[@ref12]

The harmful effects of SSBs are most prominent in the young. Notably, teenagers consume more sugar than other age groups, more than two times the recommended amount.[@ref13] Students may easily access SSBs such as carbonated soda, energy drinks, sports drinks, and highly sweetened coffees and teas at school. Such unhealthy behavior puts teenagers at risk of obesity and obesity-related diseases.[@ref14],[@ref15] Due to concerns about health-related effects of SSBs, vending machines selling soft drinks have been banned in many parts of the US. In 2014--2015, the U.S. Department of Agriculture nutritional standards for foods and beverages required US high schools participating in federally reimbursable meal programs to remove virtually all SSBs at competitive venues.[@ref16] Despite these efforts, SSB consumption continues to increase and appears to be an independent risk factor for metabolic diseases.[@ref17],[@ref18]

Obesity has emerged as a global public health concern. The prevalence of obesity is continuously increasing due to nutritional transitions in both developing and developed countries[@ref19] and has increased by 40% in men and 30% in women in the US, with greater increases in adolescents.[@ref20],[@ref21] In South Korea, the proportion of people with body mass index ≥25 kg/m^2^ was 26.0% in 1998, which increased to 29.2% in 2005 and 31.7% in 2007. Among children and adolescents \<20 years of age, the prevalence of obesity in Korea doubled over the last decade from 5.8% in 1997 to 10.9% in 2007 (Ministry of Health and Welfare: Healthy Eating Styles for Korean Adults; <https://www.mw.go.kr/front_new/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=223072&page=1>). Furthermore, the prevalence of metabolic syndrome in youths aged 12 to 19 years in South Korea increased from 4.0% in 1998 to 7.6% in 2007, along with major increases in dyslipidemia and abdominal obesity.[@ref22] Overweight and obese adolescents in the US obtain \>300 kcal per day from SSBs, an average of 15% of their total daily energy intake.[@ref23] Thus, SSB consumption is likely to be a primary contributor to obesity and metabolic diseases in the young.

Despite the great concern about health risks related to SSB consumption, the unfavorable metabolic effects of daily consumption of SSBs have not been clearly demonstrated, especially in younger people. Here, we aimed to investigate the effects of SSBs on glucose metabolism and fatty liver disease using an animal model.

METHODS
=======

Selection of SSBs
-----------------

Korean national data show that adolescents and young adults in South Korea frequently consume SSBs, including carbonated sodas, energy drinks, sports drinks, and highly sweetened coffees and teas.[@ref24] To identify a representative sample, we conducted a survey of SSB consumption among Korean high school students (n=101). The most popular beverages consumed were chocolate-added cocoa (Choco-Latte; Lotte Chilsung, Seoul, Korea), carbonated soda (Coca-Cola or Sprite; The Coca-Cola Company, Atlanta, GA, USA), and sweetened milk coffee (Maxwell, Dongsuh, Seoul, Korea; Let's Be, Lotte Chilsung; Santa Fe, Paldo Food, Seoul, Korea). We selected a representative brand from each category, Choco-Latte, Coca- Cola, and Maxwell, to investigate their impacts on development of fatty liver and glucose metabolism. The volume of one portion, total calories, sugar content, and proportion of sugar contained in each beverage are shown in [Table 1](#T1){ref-type="table"}. Each drink contains between 11 and 18 g of sugar per 100 g.

Experimental design and animal care
-----------------------------------

Forty male C57BL/6 mice aged 7 weeks (Japan SLC, Shizuoka, Japan) were used in the study. All mice were maintained at a temperature of 22°C±2°C and 55%±10% humidity under a 12:12-hour light-dark cycle and were allowed food and water ad libitum for the duration of the treatment period.

After being matched for weight, study mice were divided into two groups: one group was fed a normal chow diet and the second a high-fat diet. Each group was further divided into four subgroups with various treatments: water, equivalent of two cans of Coca-Cola, equivalent of two cans of Maxwell, and equivalent of two packs of Choco-Latte. Therefore, there were eight groups total, with five mice per group. At 8 AM each day, treatment beverages were administered to study animals using a feeding device. The amount of beverage administered to mice was calculated based on body weight according to a commonly used conversion between humans (60 kg) and mice (20 g). At the end of the 13-week treatment, the mice were anesthetized with an intraperitoneal injection of a mixture of zolazepam/tiletamine (80 mg/kg, Zoletil 50; Virbac, Carros, France) and xylazine (20 mg/kg, Rompun; Bayer HealthCare, Leverkusen, Germany) for euthanasia.

This study was approved by the Institutional Animal Care and Use Committee of Seoul National University Bundang Hospital (No. 51-2015-031). Experiments were performed in compliance with the Guide for Experimental Animal Research of the Laboratory for Experimental Animal Research, Clinical Research Institute, Seoul National University Bundang Hospital, Korea.

Body weight, body composition, and food intake measurements
-----------------------------------------------------------

During the 13-week treatment, body weight was measured once per week. Food and water intakes of all mice in each study group were also measured every week throughout the treatment period. Body composition was determined by dual-energy X-ray absorptiometry using a PIXImus II apparatus (GE Lunar Corp., Madison, WI, USA) at the end of the treatment period.

Biochemical markers associated with cardiovascular risk
-------------------------------------------------------

Fasting blood glucose concentration was measured every third week using a glucometer (Accu-Chek Inform II Blood Glucose Meter; Roche Diagnostics, Mannheim, Germany). The mice were subjected to an intraperitoneal glucose tolerance test after 13 weeks of treatment. Each animal was injected intraperitoneally with 1.[@ref5] g/kg of a 50 mol/L glucose solution. Blood samples (about 10 μL) were collected from an incision in the tail at 0, 15, 30, 60, 90, and 120 minutes after the glucose load. The area under the curve for glucose (AUC~glucose~) was calculated from 0 to 120 minutes using the trapezoid rule for glucose data.

An insulin tolerance test (ITT) was also conducted at the end of the treatment period. The mice were intraperitoneally injected with insulin (1 U/kg; Humalog, Eli Lilly, Indianapolis, IN, USA) after 4 to 5 hours of fasting. Blood glucose level was measured at 0, 15, 30, 60, 90, and 120 minutes after insulin administration.

Blood samples were collected from mice after 8 hours of fasting at the end of the treatment period. Plasma glucose concentration was measured using a glucose oxidase method (YSI 2300-STAT; YSI, Yellow Springs, OH, USA) immediately after the blood was drawn. Insulin level was measured at baseline and at the end of the treatment period using a mouse-specific radioimmunoassay kit (Millipore, Billerica, MA, USA). Lipid profiles (triglycerides, highdensity lipoprotein-cholesterol, and low-density lipoprotein-cholesterol), liver enzymes (aspartate \[AST\] and alanine aminotransferase \[ALT\]), and serum creatinine concentrations were determined using enzymatic procedures (Hitachi 747 Chemistry Analyzer; Hitachi, Tokyo, Japan). The levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) were measured using a Multiplex Assay Kit (RADPK-81K; Millipore). Adiponectin and high-sensitivity C-reactive protein (hsCRP) concentrations were measured using enzyme-linked immunosorbent assay kits developed by Millipore and BD Biosciences Pharmingen (Heidelberg, Germany), respectively. To estimate pancreatic β-cell function and insulin resistance, the homeostasis assessment of insulin resistance (HOMA-IR) and homeostasis assessment of β-cell function (HOMA-β) were calculated using fasting insulin and glucose levels.[@ref25]

Histology of liver and adipose tissues
--------------------------------------

After 13 weeks of treatment, liver and visceral adipose tissues were harvested to investigate the effects of SSBs on histology. Tissue samples were fixed in formalin, routinely processed, and embedded in paraffin. Paraffin-embedded sections (4 μm) were stained with hematoxylin and eosin (H&E). The area of lipid droplets that had accumulated in the liver was measured using a microscope for image acquisition and corresponding software for quantification (Image J software; National Institutes of Health, Bethesda, MD, USA).[@ref26] The sizes of fat cells in abdominal visceral fat were measured using the same software. Crown-like structures, which indicate clustering of inflammatory cells, were identified.

Immunofluorescence staining of CD68
-----------------------------------

Deparaffinized and rehydrated sections were steamed in target retrieval solution (pH 9.0; Dako, Carpinteria, CA, USA) for antigen retrieval and washed in phosphate-buffered saline. The sections were blocked with 5% normal goat serum (Gibco-BRL, Rockville, MD, USA) for 2 hours at room temperature (RT), incubated with primary antibody overnight at 4°C, and then incubated with secondary antibody for 1 hour at RT. Anti-CD68 antibody (Abcam, Cambridge, MA, USA) was used as the primary antibody. Alexa 488-conjugated goat anti-rabbit IgG (Invitrogen, Grand Island, NY, USA) was used as the secondary antibody. After mounting in Vectashield mounting medium containing DAPI (4′,6-diamidino-2-phenylindole; Vector Laboratories, Burlingame, CA, USA), images were acquired using a fluorescence microscope (IX81; Olympus, Tokyo, Japan).

Western blot analysis
---------------------

Tissues were lysed in lysis buffer, and protein concentration was determined using a protein assay kit (Pierce Biotechnology, Rockford, IL, USA). Proteins (30 μg) were resolved on 10% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and transferred onto a PVDF membrane (Millipore). Nonspecificbinding sites on the membrane were blocked in tris buffered saline with Tween (TBS-T) 20 containing 5% bovine serum albumin for 2 hours at RT and incubated with the primary antibody overnight at 4°C. After three washes with TBS-T, the membrane was blocked and incubated with the secondary antibody for 1 hour at RT. The following primary antibodies were used: anti-Akt, anti-phospho-Akt, anti-glycogen synthase kinase-3β (GSK3β), and antiphospho-GSK3β antibodies (Cell Signaling Laboratories, Beverly, MA, USA). Horseradish peroxidase-conjugated anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as the secondary antibody.

Quantitative real-time polymerase chain reaction for genes related to metabolism, inflammation, and endoplasmic reticulum stress
--------------------------------------------------------------------------------------------------------------------------------

Total RNA was extracted from tissue samples using an Isol-RNA Lysis Reagent (5 Prime, Gaithersburg, MD, USA) according to the manufacturer's recommendations. From 1 μg of total RNA, complementary DNA (cDNA) was synthesized using an iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). The expression of adiponectin, IL-6, C/EBP homologous protein (CHOP), and MCP-1 in the abdominal visceral adipose tissue and the expression of CHOP, glucose-regulated protein-78 (GRP78), and sterol regulatory element binding transcription factor-1c (SREBP1c) in the liver were analyzed using a Power SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK) on an ABI 7500 system (Applied Biosystems). We used 18S rRNA as an internal control.

Statistical analysis
--------------------

Results are reported as mean±standard deviation or standard error of the mean where indicated. Analysis of variance with post-hoc analysis was used to determine significant mean differences among groups. A commercial statistical package was used for statistical analysis IBM SPSS version 20.0 (IBM Corp., Armonk, NY, USA). A *P*\<0.05 was considered significant in all tests of statistical inference.

RESULTS
=======

Effect of SSBs on body weight
-----------------------------

For 13 weeks, starting from 7 weeks of age, weight changes were compared between control, carbonated soda, sweetened milk coffee, and chocolate-added cocoa treatment groups ([Fig. 1](#F1){ref-type="fig"}). The mice fed a high-fat diet significantly increased in weight during the treatment period compared with those allowed a normal chow diet. The SSB-treated groups treated with chocolate-added cocoa or sweetened milk coffee showed greater increases in body weight compared to the group treated with water, and the differences were more prominent in those allowed a high-fat diet. At the end of the treatment period, body weight of the chocolate-added cocoa group had increased to a significantly greater extent compared with the other three groups allowed a high-fat diet ([Fig. 1A](#F1){ref-type="fig"}).

Body fat percentages were higher in the three groups treated with SSBs than in the control group, and the differences were more prominent in those allowed a high-fat diet ([Fig. 1B](#F1){ref-type="fig"}). In those allowed a high-fat diet, body fat percentages in the groups treated with chocolate-added cocoa or sweetened milk coffee increased more than in the group treated with carbonated soda.

Effects of SSBs on blood glucose, glycemic excursion, and insulin tolerance
---------------------------------------------------------------------------

We analyzed the effects of SSBs on glucose homeostasis. At the end of the treatment period, fasting blood glucose level in all SSB groups was significantly increased compared with the control group ([Supplementary Fig. 1A](#S1){ref-type="supplementary-material"}). Of the three SSB-treated groups fed a normal chow diet, blood glucose level during the glucose tolerance test and ITT did not differ significantly from that of the control group ([Supplementary Fig. 1B, C](#S1){ref-type="supplementary-material"}). Under the high-fat diet condition, blood glucose level during the glucose tolerance test increased more at 15, 30, and 60 minutes in all three SSB-treated groups than it did in the control group ([Supplementary Fig. 1B](#S1){ref-type="supplementary-material"}). The AUC~glucose~ was also higher in the three SSB-treated groups than in the control group. Glucose level in the ITT was higher in the chocolate-added cocoa and sweetened milk coffee groups than in the control group, particularly at 0, 15, 30, and 60 minutes ([Supplementary Fig. 1C](#S1){ref-type="supplementary-material"}). Those in the carbonated soda group had higher glucose level than the control group at 60 minutes.

Effects of SSBs on overall food and water intake
------------------------------------------------

We determined cumulative food and water intakes in the four treatment groups. There were no significant differences in food or water consumption between the mice fed a normal chow diet, except at 16 and 17 weeks of treatment ([Supplementary Fig. 2](#S1){ref-type="supplementary-material"}). In contrast, there were significant increases in food and water consumption in the chocolate-added cocoa group and sweetened milk coffee group from 4 to 5 weeks of treatment compared with the control group or carbonated soda-fed groups allowed access to a high-fat diet. Thus, the milk-containing beverage groups (sweetened milk coffee and chocolate-added cocoa) showed a trend toward higher cumulative caloric intake of food and drinks compared with the control and carbonated soda groups, particularly when allowed a high-fat diet.

Effects of SSBs on biochemical parameters
-----------------------------------------

When fed a normal chow diet, fasting glucose and insulin levels were higher in SSB-treated groups than controls, resulting in high HOMA-IR and low HOMA-β. Liver enzyme activities of AST and ALT and circulating levels of triglycerides, hsCRP, and MCP-1 were also higher in these groups than they were in control mice ([Table 2](#T2){ref-type="table"}).

When fed a high-fat diet, the differences in glucose, insulin, AST, ALT, triglycerides, and MCP-1 levels between the SSB-treated groups and control mice were more prominent. HOMA-IR increased substantially in mice in the SSB-treated groups allowed a high-fat diet compared to mice fed a normal chow diet. Adiponectin level was lower and TNF-α level was higher in the SSB-treated groups than in controls ([Table 3](#T3){ref-type="table"}).

Effects of SSB supplementation on liver and adipose tissue histology
--------------------------------------------------------------------

Liver sections from mice either on a normal chow diet or a high-fat diet were stained by H&E at the end of the treatment ([Fig. 2A](#F2){ref-type="fig"}). After 13 weeks of treatment, the area of lipid droplets in the livers of mice in the SSB-treated groups was larger than in control mice allowed a high-fat diet ([Fig. 2B](#F2){ref-type="fig"}).

After 13 weeks of treatment, the fat cells in abdominal visceral adipose tissue were larger in the three SSB-treated groups than in control mice ([Fig. 3](#F3){ref-type="fig"}). Crown-like structures were found in mice in the three SSB-treated groups but not in the control group. These differences were only observed in mice fed a high-fat diet and not in those fed a normal chow diet (data not shown).

Immunofluorescence staining of CD68 in adipose tissue
-----------------------------------------------------

[Supplementary Fig. 3](#S1){ref-type="supplementary-material"} shows immunofluorescence staining results for inflammatory cells. The number of CD68-positive cells increased in mice in the three SSB-treated groups compared with mice treated with water.

Relative expression of pAKT and pGSK in muscle of mice allowed a high-fat diet
------------------------------------------------------------------------------

We investigated the relative expression of pAKT and pGSK in the muscle tissues of the four treatment groups ([Supplementary Fig. 4](#S1){ref-type="supplementary-material"}). The pAKT to AKT ratio was markedly lower in the SSB-treated groups than in the control group. Moreover, the levels in mice treated with chocolate-added cocoa or sweetened milk coffee were further attenuated compared with those in mice treated with carbonated soda ([Supplementary Fig. 4B](#S1){ref-type="supplementary-material"}). The pGSK to GSK ratio was also significantly lower in the SSB-treated groups than it was in the control group. Significant differences were observed only in mice fed a high-fat diet and not in those fed a normal chow diet (data not shown).

Effects of SSB treatment on expression of genes related to metabolism, inflammation, endoplasmic reticulum stress, and lipid metabolism in adipose tissue and liver
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

The level of expression of adiponectin in visceral adipose tissue was significantly lower and the levels of IL-6 and CHOP were significantly higher in the three SSB-treated groups compared with the control group for mice fed a high-fat diet ([Supplementary Fig. 5](#S1){ref-type="supplementary-material"}). There were no significant differences in levels between the SSB-treated groups. However, MCP-1 expression in visceral adipose tissue was increased only in mice treated with carbonated soda or sweetened milk coffee compared with controls.

In the liver, the levels of expression of CHOP and GRP78 mRNA were increased in the three SSB-treated groups, but MCP-1 expression was higher only in the group treated with sweetened milk coffee ([Supplementary Fig. 6](#S1){ref-type="supplementary-material"}). The expression of CHOP in the group treated with chocolate-added cocoa was greater than that in groups treated with carbonated soda or sweetened milk coffee. The expression of SREBP1c mRNA was significantly attenuated in groups treated with SSBs compared with the control groups.

DISCUSSION
==========

In the present study, treatment with SSBs for 13 weeks resulted in greater increase in body weight and blood glucose concentration than treatment with water. Mice in groups treated with SSB had greater amount of body fat and greater infiltration of inflammatory cells and deposition of fat in their livers and adipose tissue.

Based on a survey conducted for the present study, we selected a single representative of each category of beverage: Coca-Cola for carbonated sodas, Maxwell for sweetened milk coffees, and Choco-Latte for chocolate-added cocoas. After 13 weeks of treatment, in the groups of mice treated with chocolate-added cocoa and sweetened milk coffee, the increase in body weight was greater than in controls consuming either diet. The fasting blood glucose level was significantly higher in mice in the SSB-treated groups than in the control mice in both diet groups. Notably, the increases in body weight and fasting glucose level were more prominent in SSB-treated mice allowed access to a high fat diet. Fasting glucose concentration in the SSB-treated mice exceeded 7 mmol/L (126 mg/dL), which would be classified as diabetes in humans. This finding indicates that the high-fat diet exacerbated metabolic deterioration induced by SSB treatment.

A recent study has shown that high intake of sugars from SSBs, such as sugar-added tea and coffee, is associated with hyperglycemia and inflammatory markers.[@ref18] Metabolically, the harmful effects of SSBs are mostly the contribution of fructose and additional calories. In the liver, fructose easily converts to hepatic glycogen or fat, promotes lipogenesis, and worsens insulin resistance.[@ref27],[@ref28] Therefore, fructose consumption is appreciated as a risk factor for obesity or cardiometabolic diseases.[@ref29] Consistent with such concerns, adverse metabolic effects of SSBs were clearly observed in the present study, which showed increased fat accumulation in the liver and attenuated expression of genes related to insulin sensitivity in SSB-treated mice. Moreover, SSBs provide a source of de novo lipogenesis and inhibit adipose lipolysis,[@ref30],[@ref31] ultimately increasing visceral adiposity.[@ref32] The present study also found that adipocytes in mice treated with SSBs were enlarged and had more crown-like structures. These changes may also contribute to peripheral insulin resistance and inflammation.

Muscle is a primary tissue that responds to insulin after a glucose load. The SSB-treated mice showed impaired insulin signaling in muscle, as determined by AKT and GSK phosphorylation, compared to control mice. A fructose-rich diet has detrimental effects on mitochondrial function and energy metabolism in muscle.[@ref33],[@ref34] In agreement with previous findings, glucose metabolism in muscle was impaired in the mice treated with SSBs, which may contribute to development of diabetes.

Glucose and lipid metabolism are interrelated and are affected by cytokines (e.g., adiponectin, TNF-α, and IL-6) and molecules involved in inflammation, oxidative stress, and endoplasmic reticulum (ER) stress (e.g., hsCRP, MCP-1, and plasminogen activator inhibitor-1). In the present study, aggravated insulin resistance in SSB-treated mice was accompanied by increased levels of expression of CHOP, GRP78, and ER stress markers in the liver.[@ref35] Thus, SSB treatment is likely to promote inflammatory- and stress-related processes in metabolically active organs.

In the present study, we observed metabolically harmful effects of SSBs in mice fed a high-fat diet, while mice fed a normal chow diet were less affected. The biochemical and histological changes in the SSB-treated groups occurred mainly through increased fat accumulation and altered lipid metabolism in metabolically active organs. Therefore, such changes might be more exacerbated in mice fed a high-fat diet, which already have a vulnerable signaling pathway related to lipid metabolism as a result of the fat load.

The World Health Organization has advised reduction of sugar intake to avoid chronic diseases such as fatty liver disease, T2DM, and metabolic disorders.[@ref36],[@ref37] Despite great concern about the metabolic risks of added sugar, consumption of SSBs is steadily increasing, especially among younger people.[@ref4] In addition, people tend to consume diverse types of SSBs together, for example, carbonated sodas and sweetened milk coffee. This may intensify the harmful effects of these SSBs through de novo lipogenesis and inhibit adipose lipolysis,[@ref30],[@ref31] resulting in fat accumulation in the abdomen and metabolically active organs, such as liver and muscle.[@ref32] The combined consumption of SSBs may also aggravate inflammation and insulin resistance by altering expression of related genes, such as IL-6 and MCP-1.[@ref38]

Given that SSBs are consumed mainly by adolescents and young adults, and their negative effects emerge as quickly as 3 months, it would be prudent to advise teenagers to consume less SSBs. This would be one of the most effective strategies to avoid further increases in metabolic diseases such as fatty liver, dyslipidemia, and diabetes mellitus.

The strengths of the present study are as follows. First, application of in-depth evaluation of body composition and histological assessments of liver and fat tissue produced a comprehensive analysis of the metabolic effects of SSBs. Second, the SSBs used in this study were chosen based on a survey conducted in a high school in Korea and thus may reflect actual consumption. Finally, experiments were performed using groups of mice fed a normal diet or a high-fat diet, which demonstrated differences in effects of SSBs based on type of diet.

Nonetheless, one possible limitation of this research is that a 13-week treatment period might have been insufficient. Conducting the experiment for a longer period would have made it possible to observe the effects of chronic exposure to SSBs.

In conclusion, the equivalent of two cans or packs of SSBs consumed daily for 13 weeks led to harmful biochemical and histological effects on energy homeostasis. These effects included increased body weight and body fat along with infiltration of inflammatory cells, which induced fat accumulation in the liver and ultimately impaired insulin sensitivity. Expression of genes related to energy metabolism, inflammation, and ER stress was affected unfavorably by SSB treatment. These changes may confer a greater risk of future metabolic disease in exposed persons. Thus, concerns regarding the harmful effects of SSB consumption are warranted.
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![Changes in weight during treatment (A) and body fat percentage at the end of the treatment (B) in mice treated with water, chocolate-added cocoa, sweetened milk coffee, and carbonated soda on a normal chow diet or high-fat diet (\*vs. water; ^†^vs. carbonated soda; ^‡^vs. sweetened milk coffee, all *P*\<0.05). (C) Representative photos of dual-energy X-ray absorptiometry for body fat measurement.](JOMES-29-026-f1){#F1}

![(A) Liver histology by H&E staining. All images were acquired at × 200 (n= 5 per group). (B) The percentage area of lipid droplets in the liver (% of total area). Values are presented as mean± standard error of mean. \**P*\<0.05 vs. water; ^†^*P*\<0.05 vs. carbonated soda.](JOMES-29-026-f2){#F2}

![(A) Histology of abdominal visceral adipose tissue stained with H&E in high-fat diet groups (n= 5 per group). The arrows indicate crown-like structures. (B) Comparison of fat cell size (% of control). Values are presented as mean±standard error of mean. \**P*\<0.05 vs. control (water).](JOMES-29-026-f3){#F3}

###### 

Beverages used in the study and their nutritional components

  Variable                                                                                                      Carbonated soda (Coca-Cola)   Sweetened milk coffee (Maxwell)   Chocolate-added cocoa (Choco-Latte)
  ------------------------------------------------------------------------------------------------------------- ----------------------------- --------------------------------- -------------------------------------
  Volume (mL)/can or pack                                                                                       250                           175                               235
  Total calories (kcal)/can or pack                                                                             112                           65                                160
  Sugar                                                                                                                                                                         
  Amount (g)/can or pack                                                                                        27                            13                                27
  Amount/volume (g/mL)                                                                                          0.108                         0.074                             0.115
  Protein                                                                                                                                                                       
  Amount (g)/can or pack                                                                                        0                             1                                 3.5
  Amount/volume (g/mL)                                                                                          \-                            0.006                             0.015
  Fat                                                                                                                                                                           
  Amount (g)/can or pack                                                                                        0                             1.4                               2.5
  Amount/volume (g/mL)                                                                                          \-                            0.008                             0.011
  Saturated fat                                                                                                                                                                 
  Amount (g)/can or pack                                                                                        0                             0.7                               2.5
  Amount/volume (g/mL)                                                                                          \-                            0.004                             0.011
  Cholesterol                                                                                                                                                                   
  Amount (mg)/can or pack                                                                                       0                             5                                 8
  Amount/volume (mg/mL)                                                                                         \-                            0.029                             0.034
  Sodium (mg)                                                                                                   15                            85                                150
  Daily amount administered to mice equivalent to 2 cans or packs for humans[\*](#t1fn1){ref-type="table-fn"}                                                                   
  Administered volume (mL)[†](#t1fn1){ref-type="table-fn"}                                                      0.17                          0.12                              0.16
  Administered sugar (mg)                                                                                       18.0                          8.7                               18.0
  Administered protein (mg)                                                                                     0                             0.7                               2.3
  Administered fat (mg)                                                                                         0                             0.9                               1.7
  Administered saturated fat (mg)                                                                               0                             0.5                               1.7
  Administered cholesterol (mg)                                                                                 0                             0.0033                            0.0053

Volume was calculated using translation from human (60 kg) to 5-week-old mouse (20 g); ^†^Rounded to three decimal points.

###### 

Weight and biochemical measurement including glucose homeostasis, inflammatory markers, and adiponectin levels in treatment groups of mice fed a normal chow diet after 13 weeks

  Variable                                  Control (water)   Carbonated soda (Coca-Cola)                    Sweetened milk coffee (Maxwell)                 Chocolate-added cocoa (Choco-Latte)
  ----------------------------------------- ----------------- ---------------------------------------------- ----------------------------------------------- -----------------------------------------------
  Weight (g)                                23.3 ± 3.6        25.6 ± 3.6[\*](#t2fn2){ref-type="table-fn"}    27.0 ± 3.2[\*,†](#t2fn2){ref-type="table-fn"}   28.2 ± 3.6[\*,†](#t2fn2){ref-type="table-fn"}
  Fasting glucose (mmol/L)                  4.9 ± 0.8         5.1 ± 1.1[\*](#t2fn2){ref-type="table-fn"}     5.3 ± 1.2[\*](#t2fn2){ref-type="table-fn"}      6.1 ± 1.3[\*](#t2fn2){ref-type="table-fn"}
  Fasting insulin (µIU//L)                  9.1 ± 1.2         11.3 ± 1.3                                     11.5 ± 1.3[\*](#t2fn2){ref-type="table-fn"}     12.1 ± 1.4[\*](#t2fn2){ref-type="table-fn"}
  HOMA-IR[§](#t2fn2){ref-type="table-fn"}   1.98 ± 0.21       2.56 ± 0.36[\*](#t2fn2){ref-type="table-fn"}   2.70 ± 0.45[\*](#t2fn2){ref-type="table-fn"}    3.28 ± 0.51[\*](#t2fn2){ref-type="table-fn"}
  HOMA-β                                    131.4 ± 23.1      140.6 ± 28.3                                   129.7 ± 34.1                                    92.9 ± 23.1[\*](#t2fn2){ref-type="table-fn"}
  AST (U/L)                                 47.6 ± 8.8        57.2 ± 6.9[\*](#t2fn2){ref-type="table-fn"}    61.5 ± 9.0[\*](#t2fn2){ref-type="table-fn"}     63.1 ± 7.7[\*](#t2fn2){ref-type="table-fn"}
  ALT (U/L)                                 34.6 ± 7.7        44.4 ± 10.3[\*](#t2fn2){ref-type="table-fn"}   57.0 ± 7.2[\*,†](#t2fn2){ref-type="table-fn"}   55.0 ± 9.1[\*,†](#t2fn2){ref-type="table-fn"}
  Triglycerides (mmol/L)                    1.4 ± 0.3         1.6 ± 0.5[\*](#t2fn2){ref-type="table-fn"}     1.6 ± 0.6[\*,†](#t2fn2){ref-type="table-fn"}    1.7 ± 0.7[\*](#t2fn2){ref-type="table-fn"}
  HDL cholesterol (mmol/L)                  2.1 ± 0.3         2.0 ± 0.5                                      1.8 ± 0.5                                       1.8 ± 0.5
  LDL cholesterol (mmol/L)                  5.6 ± 0.6         5.7 ± 0.7                                      5.8 ± 0.7                                       5.9 ± 0.8
  hsCRP (mg/L)                              0.22 ± 0.25       0.56 ± 0.26[\*](#t2fn2){ref-type="table-fn"}   0.44 ± 0.14[\*](#t2fn2){ref-type="table-fn"}    0.68 ± 0.28[\*](#t2fn2){ref-type="table-fn"}
  Adiponectin (μg/mL)                       9.3 ± 2.4         7.6 ± 2.1[\*](#t2fn2){ref-type="table-fn"}     7.3 ± 2.6[\*](#t2fn2){ref-type="table-fn"}      6.7 ± 2.1[\*](#t2fn2){ref-type="table-fn"}
  TNF-α (pg/mL)                             8.1 ± 3.5         12.2 ± 6.0                                     10.3 ± 3.0[\*](#t2fn2){ref-type="table-fn"}     11.7 ± 4.4[\*](#t2fn2){ref-type="table-fn"}
  IL-6 (pg/mL)                              4.8 ± 1.1         5.8 ± 1.9                                      5.2 ± 1.2                                       5.0 ± 1.8
  MCP-1 (ng/mL)                             3.5 ± 1.7         4.8 ± 1.4[\*](#t2fn2){ref-type="table-fn"}     4.7 ± 2.1[\*](#t2fn2){ref-type="table-fn"}      5.6 ± 1.5[\*](#t2fn2){ref-type="table-fn"}

Values are presented as mean± standard deviation. Post-hoc analysis by least significant difference t-tests for mean differences between two groups.

vs. control; †vs. carbonated soda; *P*\<0.05 in all cases; §HOMA-IR= (μIU/L× mmol/L).

HOMA-IR, homeostasis assessment of insulin resistance; HOMA-β, homeostasis assessment of β-cell function; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1.

###### 

Weight and biochemical measures including glucose homeostasis, inflammatory markers, and adiponectin levels in treatment groups of mice fed a high-fat diet after 13 weeks

  Variable                                  Control (water)   Carbonated soda (Coca-Cola)                    Sweetened milk coffee (Maxwell)                 Chocolate-added cocoa (Choco-Latte)
  ----------------------------------------- ----------------- ---------------------------------------------- ----------------------------------------------- -------------------------------------------------
  Weight (g)                                27.2 ± 3.3        28.8 ± 3.7[\*](#t3fn2){ref-type="table-fn"}    30.3 ± 3.2[\*](#t3fn2){ref-type="table-fn"}     35.3 ± 5.6[\*,†,‡](#t3fn2){ref-type="table-fn"}
  Fasting glucose (mmol/L)                  6.7 ± 0.9         7.7 ± 1.2[\*](#t3fn2){ref-type="table-fn"}     7.6 ± 1.1[\*](#t3fn2){ref-type="table-fn"}      8.6 ± 1.1[\*](#t3fn2){ref-type="table-fn"}
  Fasting insulin (µIU//L)                  11.2 ± 1.0        13.5 ± 1.2[\*](#t3fn2){ref-type="table-fn"}    14.7 ± 1.3[\*](#t3fn2){ref-type="table-fn"}     16.1 ± 1.4[\*](#t3fn2){ref-type="table-fn"}
  HOMA-IR[§](#t2fn2){ref-type="table-fn"}   3.34 ± 0.82       4.63 ± 0.73[\*](#t3fn2){ref-type="table-fn"}   4.97 ± 0.81[\*](#t3fn2){ref-type="table-fn"}    6.16 ± 0.93[\*,†](#t3fn2){ref-type="table-fn"}
  HOMA-β                                    69.6 ± 13.3       64.0 ± 24.0                                    71.6 ± 19.2                                     63.1 ± 28.6
  AST (U/L)                                 49.2 ± 9.8        62.3 ± 8.2[\*](#t3fn2){ref-type="table-fn"}    68.6 ± 6.6[\*](#t3fn2){ref-type="table-fn"}     72.1 ± 8.1[\*](#t3fn2){ref-type="table-fn"}
  ALT (U/L)                                 46.6 ± 9.7        51.4 ± 11.3[\*](#t3fn2){ref-type="table-fn"}   59.3 ± 7.8[\*,†](#t3fn2){ref-type="table-fn"}   65.2 ± 5.8[\*,†](#t3fn2){ref-type="table-fn"}
  Triglycerides (mmol/L)                    1.9 ± 1.3         2.2 ± 0.8[\*](#t3fn2){ref-type="table-fn"}     2.3 ± 0.7[\*](#t3fn2){ref-type="table-fn"}      2.4 ± 0.7[\*](#t3fn2){ref-type="table-fn"}
  HDL cholesterol (mmol/L)                  1.9 ± 0.6         1.7 ± 0.5                                      1.7 ± 0.6                                       1.6 ± 0.4[\*](#t3fn2){ref-type="table-fn"}
  LDL cholesterol (mmol/L)                  5.9 ± 0.8         5.9 ± 0.7                                      6.1 ± 0.8                                       6.2 ± 1.1[\*](#t3fn2){ref-type="table-fn"}
  hsCRP (mg/L)                              0.61 ± 0.21       0.78 ± 0.16[\*](#t3fn2){ref-type="table-fn"}   0.89 ± 0.21[\*](#t3fn2){ref-type="table-fn"}    0.72 ± 0.18[\*](#t3fn2){ref-type="table-fn"}
  Adiponectin (μg/mL)                       8.3 ± 2.1         6.6 ± 2.0[\*](#t3fn2){ref-type="table-fn"}     6.3 ± 2.1[\*](#t3fn2){ref-type="table-fn"}      5.8 ± 1.7[\*,†](#t3fn2){ref-type="table-fn"}
  TNF-α (pg/mL)                             11.1 ± 3.6        13.2 ± 3.6[\*](#t3fn2){ref-type="table-fn"}    12.3 ± 4.0[\*,†](#t3fn2){ref-type="table-fn"}   15.7 ± 3.4[\*,†](#t3fn2){ref-type="table-fn"}
  IL-6 (pg/mL)                              5.8 ± 1.2         5.5 ± 1.9                                      5.8 ± 1.6                                       6.1 ± 1.8
  MCP-1 (ng/mL)                             5.5 ± 1.4         5.9 ± 1.8[\*](#t3fn2){ref-type="table-fn"}     6.7 ± 1.5[\*](#t3fn2){ref-type="table-fn"}      7.6 ± 1.5[\*,†](#t3fn2){ref-type="table-fn"}

Values are presented as mean± standard deviation. Post-hoc analysis by least significant difference t-tests for mean differences between two groups.

vs. control; ^†^vs. carbonated soda; ^‡^vs. sweetened milk coffee; *P*\<0.05 in all cases; §HOMA-IR= (μIU/L× mmol/L).

HOMA-IR, homeostasis assessment of insulin resistance; HOMA-β, homeostasis assessment of β-cell function; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1.
